CTNM Key Statistics, Chart & Performance
The current stock price of CTNM is 14.6 USD. In the past month the price increased by 28.07%. In the past year, price increased by 49.13%.
CTNM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CTNM. When comparing the yearly performance of all stocks, CTNM is one of the better performing stocks in the market, outperforming 90.76% of all stocks.
CTNM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CTNM. No worries on liquidiy or solvency for CTNM as it has an excellent financial health rating, but there are worries on the profitability.
CTNM Financial Highlights
Over the last trailing twelve months CTNM reported a non-GAAP Earnings per Share(EPS) of -2.25. The EPS decreased by -341.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.85% | ||
| ROE | -21.34% | ||
| Debt/Equity | 0 |
CTNM Forecast & Estimates
13 analysts have analysed CTNM and the average price target is 20.74 USD. This implies a price increase of 42.05% is expected in the next year compared to the current price of 14.6.
CTNM Ownership
About CTNM
Company Profile
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company is headquartered in San Diego, California and currently employs 41 full-time employees. The company went IPO on 2024-04-05. The company is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The firm is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.
Company Info
CONTINEUM THERAPEUTICS INC-A
3565 General Atomics Court, Suite 200
San Diego CALIFORNIA US
Employees: 41
Phone: 18583335280
CONTINEUM THERAPEUTICS INC-A / CTNM FAQ
What does CONTINEUM THERAPEUTICS INC-A do?
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company is headquartered in San Diego, California and currently employs 41 full-time employees. The company went IPO on 2024-04-05. The company is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The firm is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.
What is the current price of CTNM stock?
The current stock price of CTNM is 14.6 USD. The price increased by 1.18% in the last trading session.
What is the dividend status of CONTINEUM THERAPEUTICS INC-A?
CTNM does not pay a dividend.
How is the ChartMill rating for CONTINEUM THERAPEUTICS INC-A?
CTNM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does CONTINEUM THERAPEUTICS INC-A belong to?
CONTINEUM THERAPEUTICS INC-A (CTNM) operates in the Health Care sector and the Pharmaceuticals industry.
Should I buy CTNM stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CTNM.
What is the employee count for CTNM stock?
CONTINEUM THERAPEUTICS INC-A (CTNM) currently has 41 employees.